Histone Deactylase Inhibition in R-CHOP–Treated Double-Expressor Diffuse Large B-Cell Lymphoma
Mené en Chine sur 423 patients atteints d'un lymphome diffus à grandes cellules B exprimant les gènes MYC et BCL2 (âge médian : 63 ans ; durée médiane de suivi : 41,3 mois), cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité de l'ajout du tucidinostat (un inhibiteur d'histone désacétylase) à une immunochimiothérapie de première ligne de type R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, with an estimated 150 000 new cases annually worldwide.1 Patients with DLBCL typically require treatment at the time of diagnosis, and more than 60% of patients are currently cured with front-line immunochemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). However, DLBCL is highly heterogeneous, and subsets of patients who progress after front-line treatment have a substantially poorer clinical outcome. Therapeutic progress to improve the outcome of the patients with lymphoma destined to progress after initial chemotherapy has proven very difficult, with very few trials showing superiority of an experimental group over standard R-CHOP.
JAMA , éditorial, 2026